DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
13 pags, 6 figs, 1 tab. -- Supplementary information is available at the Publisher's web, Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone, an FDA-approved molecule for Parkinson's disease, as a potent TTR aggregation inhibitor. Tolcapone binds specifically to TTR in human plasma, stabilizes the native tetramer in vivo in mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including those affecting the central nervous system, for which no small-molecule therapy exists., This work was funded by the Spanish Ministry of Economy and Competitiveness (BFU2013-44763 to S.V., BFU2012-37116 to D.R., RTC-2014-1931-1 to R.I. and BFU2013-47064-P to A.V.-C.), by SUDOE INTERREG IV B (SOE4/P1/E831 to S.V. and A.V.-C.), by the Spanish Ministry of Science and Innovation (BFU2010-19451 to A.V.-C.), by Diputacion General de Aragon (Protein Targets Group B89 to A. V.-C.) and by the National Institutes of Health (NIA, AG-032285 to N. Reixach). S.V. has been granted an ICREA ACADEMIA award. SOM Biotech was funded by the Spanish Ministry of Health DIN 10-13 grant and the Catalan Competitiveness Agency FINEBT10-2-0037 grant. N. Reig and R.I. were funded by a Torres Quevedo grant by the Spanish Ministry of Economy and Competitiveness. R.S. was supported by CAPES-Science without Borders and S.E. by Consejo Nacional de Promocion Cientifica y Tecnologica (CONICET). We also thank Dr. Debora Foguel for the WT-TTR plasmid used in this study to produce recombinant WT-TTR and Dr Antoni Planas and Dr Ellen Cotrina for technical work. The human cardiac AC16 cell line was developed by Mercy M Davidson at Columbia University46. X-ray experiments were performed at the BL-13 beamline at the ALBA synchrotron in collaboration with the ALBA staff., Peer reviewed
Proyecto:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 BFU2013-44763
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 BFU2012-37116
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RTC-2014-1931-1
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 BFU2013-47064-P